Cerus (CERS) Expected to Announce Quarterly Earnings on Thursday

Cerus (NASDAQ:CERS) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Cerus to post earnings of ($0.01) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Cerus Stock Performance

Shares of CERS opened at $2.15 on Thursday. The business has a 50-day simple moving average of $2.22 and a two-hundred day simple moving average of $1.72. The company has a quick ratio of 1.29, a current ratio of 1.89 and a debt-to-equity ratio of 0.78. Cerus has a 52 week low of $1.12 and a 52 week high of $2.95. The stock has a market cap of $412.99 million, a price-to-earnings ratio of -26.88 and a beta of 1.52.

Institutional Trading of Cerus

Hedge funds have recently modified their holdings of the company. CIBC Bancorp USA Inc. acquired a new stake in shares of Cerus in the third quarter worth $31,000. Aquatic Capital Management LLC purchased a new stake in Cerus in the third quarter valued at $35,000. Dynamic Technology Lab Private Ltd acquired a new stake in Cerus during the 1st quarter worth about $32,000. HUB Investment Partners LLC acquired a new stake in Cerus during the 2nd quarter worth about $42,000. Finally, Captrust Financial Advisors raised its stake in shares of Cerus by 89.7% during the 2nd quarter. Captrust Financial Advisors now owns 31,109 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 14,709 shares during the last quarter. 78.37% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on CERS shares. Wall Street Zen raised Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. TD Cowen reissued a “buy” rating on shares of Cerus in a report on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Cerus currently has a consensus rating of “Hold” and an average price target of $4.00.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.